|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Mar 02 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Gilead Acquires Arcellx for $7.8B to Lead CAR-T Innovation
|
|
| | GSK Bolsters Respiratory Pipeline with $950M 35Pharma Buy
|
|
| | Astellas & Vir Team Up in $1.7B Oncology Power Play
|
|
| | Novo Nordisk Bets $2.1B on Oral Biologics with Vivtex
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Cover Story
|
| |
Gilead Acquires Arcellx for $7.8B
|
| |
Market-Shaping Deals & Partnerships
|
| |
| • | GSK Buys 35Pharma for $950M – Bolstering respiratory pipeline with HS235.
|
|
| • | Astellas & Vir $1.7B Oncology Alliance – Advancing VIR-5500 PSMA-targeted therapy.
|
|
| • | Novo Nordisk & Vivtex $2.1B Oral Biologics Deal – Next-gen oral therapies for metabolic diseases.
|
|
| • | Merck Restructures Oncology & Specialty Units – Driving growth with 80+ Phase III trials.
|
|
| • | Organon Secures Miudella IUD Global Rights – Expanding women’s health portfolio.
|
|
| • | Sciwind & Pfizer China GLP-1 Deal – Exclusive rights for Ecnoglutide in Mainland China.
|
|
| • | GSK siRNA Alliance with Frontier Biotechnologies – Expanding immunology pipeline.
|
|
| • | Boehringer & Sitryx $500M+ Autoimmune Deal – Next-gen small-molecule immune therapies.
|
|
| • | SteinCares-Shilpa LATAM Biosimilars Partnership – Expanding regional biologics access.
|
|
| |
Clinical & Pipeline Highlights
|
| |
| • | NRG1+ NSCLC – Zenocutuzumab (Bizengri) post-hoc eNRGy trial data.
|
|
| • | Ulcerative Colitis (UC) – Tremfya Week 140 QUASAR LTE data.
|
|
| • | Solid Tumors – IDE034 Phase I bispecific ADC trial.
|
|
| • | Ocular Myasthenia Gravis – Vyvgart Phase III ADAPT OCULUS data.
|
|
| • | HIV – Lotivibart + cabotegravir LA 12-month EMBRACE data.
|
|
| • | mCRPC (Bone Metastases) – Xofigo + enzalutamide PEACE-3 trial results.
|
|
| • | Prurigo Nodularis – Nemluvio 4-year OLYMPIA LTE data.
|
|
| |
Regulatory & Approval Spotlight
|
| |
| • | Rare Diseases & Oncology Approvals – Bysanti, Calquence, Loargys, Imaavy, Dupixent, Braftovi, Linerixibat, Bepirovirsen, Hernexeos, Olezarsen.
|
|
| • | Cara Medical CARA System – FDA 510(k) clearance for 3D cardiac mapping.
|
|
| • | DRL_AB Biosimilar – FDA accepts BLA for interchangeable Orencia biosimilar.
|
|
| • | Merck Animal Health Numelvi – FDA approval for canine allergic dermatitis.
|
|
| |
|
| |
|
| |
|
| |
Celebrating Innovation and Excellence Across the Global Pharma & Healthcare Industry
|
| |
We are thrilled to announce the PharmaShots Pharma Awards 2026, a premier virtual event dedicated to recognizing groundbreaking innovation, leadership, and excellence in the pharmaceutical and healthcare sectors worldwide.
|
| |
This prestigious initiative brings together industry leaders, innovators, and key decision-makers from around the globe, creating a unique platform to celebrate achievements and set new benchmarks for the industry.
|
| |
Why Partner with PharmaShots Pharma Awards?
|
| |
Our sponsorship opportunities allow partners to:
|
| |
| • | Showcase your brand in front of a highly engaged, global pharma audience.
|
|
| • | Position your organization as a leader in innovation and thought leadership.
|
|
| • | Gain exclusive networking access to decision-makers, innovators, and influencers shaping the future of healthcare.
|
|
| |
We are currently reaching out to potential sponsors to understand your engagement goals and preferred sponsorship avenues. Based on your input, our team will provide a customized sponsorship prospectus detailing benefits, opportunities, and recommended next steps.
|
| |
Date of Awards Announcement: May 1, 2026
|
| |
We invite organizations to join us in this landmark celebration. Your support will help us highlight excellence, inspire innovation, and strengthen connections across the global pharma ecosystem.
|
| |
Interested in exploring sponsorship opportunities?
Partner with us at the PharmaShots Pharma Awards, fill out your sponsorship form here
|
| |
|
| |
|
| |
Gilead’s $7.8B CAR-T Power Play
|
| |
|
| |
Gilead Sciences takes a commanding step toward CAR-T dominance with its $7.8B acquisition of Arcellx, securing full rights to the anti-BCMA anito-cel therapy and the proprietary D-Domain CAR platform.
|
| |
Why It Matters
|
| |
| • | Deal Structure: $115/share tender plus $5/share CVR tied to $6B anito-cel sales by 2029.
|
|
| • | Regulatory Catalyst: BCMA CAR-T BLA accepted; PDUFA set for Dec 23, 2026 (iMMagine-1 data).
|
|
| • | Equity Move: Builds on Gilead’s existing ~11.5% stake; transaction expected to close in 2026.
|
|
| • | Valuation: Implied $7.8B for full control of a high-potential CAR-T franchise.
|
|
| |
Strategic Implications
|
| |
| • | D-Domain Platform: Advances CAR-T stability, precision, and safety, enabling broader clinical applications.
|
|
| • | Multiple Myeloma Focus: Positions Gilead for leadership in fourth-line r/r myeloma treatment.
|
|
| • | Pipeline Expansion: Accelerates next-gen oncology and cell therapy programs.
|
|
| • | High-Conviction Bet: Secures a differentiated CAR-T advantage against competitors.
|
|
| |
This bold move signals Gilead’s intent to lead the CAR-T revolution in hematologic malignancies, combining cutting-edge science with strategic scale to dominate the cell therapy landscape.
|
| |
|
| |
| | GSK Inhales $950M Deal to Supercharge Respiratory Pipeline
|
|
|
|
|
| |
GSK's $950M 35Pharma Buy Bolsters Respiratory Pipeline
|
| |
|
| |
In a strategic expansion of its Respiratory, Immunology & Inflammation portfolio, GSK has agreed to acquire 35Pharma for $950M cash, gaining full rights to lead asset HS235.
|
| |
Why It Matters
|
| |
| • | Cash Deal: $950M payable at closing.
|
|
| • | HS235 Progress: Phase I complete in healthy volunteers; Phase II prep for PAH/HFpEF.
|
|
| • | Novel Mechanism: Targets activin receptor signaling pathway.
|
|
| • | Pipeline Boost: Adds differentiated cardiopulmonary therapy.
|
|
| |
Strategic Focus
|
| |
| • | Unmet Need: Addresses limited options in pulmonary hypertension.
|
|
| • | GSK Strategy: Disciplined bet on immune/inflammatory innovation.
|
|
| • | 35Pharma Validation: Accelerates HS235 via global pharma leadership.
|
|
| • | Franchise Growth: Strengthens specialty care durability.
|
|
| |
This acquisition positions GSK to pioneer activin-targeted advances in respiratory diseases.
|
| |
|
| |
| | Pipeline Power Plays: From PSMA to Oral Biologics, Pharma Stakes Big
|
|
|
|
|
| |
$1.7B Power Play: Astellas & Vir Unite for VIR-5500
|
| |
|
| |
In a decisive oncology push, Astellas Pharma has teamed up with Vir Biotechnology to accelerate development of VIR-5500, a next-generation PRO-XTEN dual-masked CD3 T-cell engager targeting PSMA for prostate cancer.
|
| |
Why It Matters
|
| |
| • | Cost Sharing: Astellas funds 60% of global development; Vir covers 40%.
|
|
| • | Trial Transition: Vir leads Phase I; Astellas takes over post-transition.
|
|
| • | U.S. Co-Promotion: Vir retains option for equal profit/loss sharing.
|
|
| • | Big Economics: $335M upfront/near-term (cash, premium equity, milestone); up to $1.37B milestones + tiered royalties ex-U.S.
|
|
| |
Strategic Focus
|
| |
| • | Tumor Selectivity: Dual-masked design boosts PSMA targeting, cuts off-tumor toxicity.
|
|
| • | Pipeline Boost: Expands Astellas' oncology assets; validates Vir's PRO-XTEN platform.
|
|
| • | PSMA Competition: Positions both in heated prostate cancer race.
|
|
| • | Sanofi Tie-In: Shares portion of proceeds per existing license.
|
|
| |
This deal signals conviction in VIR-5500's potential to reshape PSMA-targeted therapies, blending Vir's innovation with Astellas' development scale to lead the prostate cancer frontier.
|
| |
Merck Overhaul: Oncology and Specialty Units Fuel Growth Surge
|
| |
|
| |
In a strategic overhaul to sharpen focus and accelerate execution, Merck has reorganized its Human Health division into two powerhouses: Oncology and Specialty, Pharma & Infectious Diseases.
|
| |
Why It Matters
|
| |
| • | Structural Split: Separates Oncology from Specialty/Pharma/Infectious Diseases for agility.
|
|
| • | Leadership Alignment: Jannie Oosthuizen leads Oncology & MSD International; Brian Foard heads Specialty unit.
|
|
| • | Pipeline Momentum: ~80 Phase III trials; 20+ growth drivers incoming.
|
|
| • | Execution Edge: Enables faster decisions, sharper commercial focus.
|
|
| |
Strategic Focus
|
| |
| • | Oncology Dominance: Sustains Merck's cancer care leadership.
|
|
| • | Growth Pillar: Builds Specialty/Infectious Diseases portfolio for rapid launches.
|
|
| • | Lifecycle Precision: Optimizes franchise management across high-value areas.
|
|
| • | Long-Term Play: Positions divisions for collective growth trajectory.
|
|
| |
With pipeline depth, clear leadership, and agile structure, Merck is primed for its next wave of blockbuster performance.
|
| |
Women’s Health Boost: Organon Secures Global Rights to Miudella IUD
|
| |
|
| |
In a decisive move to strengthen its women’s health portfolio, Organon has secured exclusive global rights to Miudella—a hormone-free copper IUD contraceptive from Sebela Pharmaceuticals.
|
| |
Why It Matters
|
| |
| • | FDA Nod: Approved Feb 2025 for up to 3 years of pregnancy prevention.
|
|
| • | Deal Value: $27.5M upfront; up to $505M sales milestones + tiered double-digit royalties.
|
|
| • | Design Edge: Flexible frame with preloaded inserter for easier placement.
|
|
| • | Market Potential: Taps rising demand for long-acting, hormone-free options.
|
|
| |
Strategic Focus
|
| |
| • | Portfolio Expansion: Bolsters Organon’s non-hormonal contraception lineup.
|
|
| • | Global Reach: Leverages Organon’s commercial footprint worldwide.
|
|
| • | Value Unlock: Delivers near/long-term upside for Sebela via milestones/royalties.
|
|
| • | Innovation Fit: Aligns access, ease, and scale in women’s health.
|
|
| |
This deal positions Miudella to capture growing global demand for innovative, hormone-free contraception.
|
| |
China GLP-1 Push: Sciwind Partners Pfizer for Ecnoglutide Rights
|
| |
In a strategic move to accelerate market penetration in China’s booming metabolic space, Sciwind Biosciences has granted Pfizer China exclusive commercialization rights to Ecnoglutide injection in Mainland China.
|
| |
Why It Matters
|
| |
| • | NMPA Approval: Cleared Jan 2026 for type 2 diabetes in adults.
|
|
| • | Deal Economics: Up to $495M in upfront, regulatory, sales milestones.
|
|
| • | GLP-1 Design: cAMP-biased agonist for optimized signaling.
|
|
| • | Obesity Potential: MAA under review for chronic weight management.
|
|
| |
Strategic Focus
|
| |
| • | Sciwind Control: Retains R&D, regulatory, manufacturing, supply leadership.
|
|
| • | Pfizer Scale: Leverages commercial muscle in China's GLP-1 boom.
|
|
| • | Metabolic Expansion: Targets diabetes/obesity growth markets.
|
|
| • | High-Stakes Play: Captures surging demand in China's disease burden.
|
|
| |
This alliance blends Sciwind's innovation with Pfizer's reach to dominate China's GLP-1 wave.
|
| |
GSK's $1B siRNA Bet: Frontier Alliance Bolsters Immunology Pipeline
|
| |
In a bold move to deepen its immunology pipeline, GSK has secured exclusive global rights to two siRNA assets from Frontier Biotechnologies—one IND-stage and one preclinical.
|
| |
Why It Matters
|
| |
| • | Headline Value: $40M upfront; up to $963M milestones + tiered royalties.
|
|
| • | Global Exclusivity: GSK gains worldwide dev/manufacturing/commercial rights.
|
|
| • | siRNA Modality: Targets gene silencing for durable immunology control.
|
|
| • | Early Progress: Frontier leads initial Phase I (China) and IND-enabling studies.
|
|
| |
Strategic Focus
|
| |
| • | Transition Model: GSK assumes global clinical/regulatory/commercial post-Frontier handover.
|
|
| • | Pipeline Depth: Advances GSK's next-gen immunology platforms.
|
|
| • | Frontier Validation: Unlocks milestone upside for RNAi expertise.
|
|
| • | Precision Play: Positions siRNA to redefine immune disease standards.
|
|
| |
This high-conviction alliance merges Frontier's innovation with GSK's scale to lead siRNA in immunology.
|
| |
Novo Nordisk's $2.1B Oral Biologics Bet with Vivtex
|
| |
|
| |
In a high-stakes push to redefine metabolic care, Novo Nordisk has partnered with Vivtex to develop next-generation oral biologics for obesity, diabetes, and comorbidities.
|
| |
Why It Matters
|
| |
| • | Platform Power: Vivtex's GI screening, formulation, AI modeling for oral bioavailability.
|
|
| • | Deal Scale: Upfronts, research funding, up to $2.1B milestones + tiered royalties.
|
|
| • | Novo Leadership: Handles global dev, regulatory, manufacturing, commercialization.
|
|
| • | Biologics Breakthrough: Enables pill-based large-molecule delivery.
|
|
| |
Strategic Focus
|
| |
| • | Metabolic Expansion: Builds on Novo's dominance beyond injectables.
|
|
| • | Patient-Friendly: Targets simpler, precise therapies for obesity/diabetes.
|
|
| • | Vivtex Validation: Scales platform in high-competition space.
|
|
| • | Transformative Edge: Merges delivery tech with metabolic expertise.
|
|
| |
This alliance bets big on oral biologics to revolutionize patient access in metabolic diseases.
|
| |
Boehringer's $500M+ Autoimmune Deal with Sitryx
|
| |
In a strategic expansion of its immunology pipeline, Boehringer Ingelheim has secured exclusive global rights to Sitryx Therapeutics' preclinical small-molecule inhibitor for multiple autoimmune/inflammatory diseases.
|
| |
Why It Matters
|
| |
| • | Disease-Modifying Aim: Targets underlying immune dysfunction, not just symptoms.
|
|
| • | Full Control: Boehringer leads research, clinical dev, regulatory, commercialization.
|
|
| • | Financial Upside: Upfront/near-term + >$500M milestones; tiered royalties.
|
|
| • | Small-Molecule Edge: Oral, scalable alternative to biologics.
|
|
| |
Strategic Focus
|
| |
| • | Broad Indications: Spans high-unmet-need autoimmune/inflammatory areas.
|
|
| • | Boehringer Commitment: Bolsters long-term immunology innovation.
|
|
| • | Sitryx Validation: Scales platform via major pharma partner.
|
|
| • | Next-Gen Bet: Advances precision immune modulation.
|
|
| |
This alliance positions Boehringer to pioneer disease-modifying oral therapies in immunology.
|
| |
SteinCares-Shilpa Alliance Expands LATAM Biosimilars Reach
|
| |
|
| |
In a strategic move to boost biosimilar access in Latin America, SteinCares has secured exclusive licensing rights from Shilpa Medicare to commercialize a biosimilar across key LATAM markets.
|
| |
Why It Matters
|
| |
| • | Exclusive Rights: SteinCares handles registration, commercialization, distribution.
|
|
| • | Shilpa Expertise: Leads development, manufacturing at Dharwad, India facility.
|
|
| • | Regional Platform: Leverages SteinCares' LATAM regulatory/commercial network.
|
|
| • | Access Focus: Targets affordability challenges in biologics.
|
|
| |
Strategic Focus
|
| |
| • | Complementary Strengths: Blends Shilpa's biologics scale with SteinCares' local reach.
|
|
| • | Speed to Market: Accelerates timelines for advanced therapies.
|
|
| • | Portfolio Growth: Expands Shilpa's global biosimilars footprint.
|
|
| • | SteinCares Leadership: Solidifies specialty pharma role in LATAM.
|
|
| |
This partnership delivers high-quality, cost-effective biosimilars to LATAM patients at scale.
|
| |
| | Trailblazing Trials: Next-Gen Therapies in Action
|
|
|
|
|
| |
Post-Hoc eNRGy Trial
|
| |
|
| |
NRG1+ NSCLC
|
| |
Partner Therapeutics reports compelling post-hoc eNRGy trial data for zenocutuzumab (Bizengri; ≥3 doses beyond progression) in advanced NRG1 fusion-positive NSCLC (n=27).
|
| |
Key Details
|
| |
| • | 81% oligoprogression; 19% diffuse progression.
|
|
| • | Median drug exposure: ~10 months post-progression (vs. ~7 months pre-progression).
|
|
| • | 8 patients on therapy >6 months post-progression (one >23 months; one ~4 years); 22% continued after local lesion management.
|
|
| |
Next Steps
Strengthens Bizengri positioning in high-need NRG1+ niche.
|
| |
Asset Snapshot
Durable benefit via sustained HER2/HER3 pathway suppression beyond progression.
|
| |
These findings, presented at IASLC TTLC 2026, highlight zenocutuzumab’s potential for precision therapy in rare molecular NSCLC subsets.
|
| |
Ulcerative Colitis (UC)
|
| |
|
| |
Johnson & Johnson unveils Week 140 QUASAR LTE data for Tremfya (guselkumab; IV 200 mg induction Q4W → SC 100/200 mg maintenance) vs. placebo in moderate-to-severe active UC (~89% completion rate).
|
| |
Key Details
|
| |
| • | Clinical remission: 80.8%; histo-endoscopic mucosal improvement (HEMI): 78.6%; endoscopic remission: 53.6%.
|
|
| • | Most remitters steroid-free ≥8 weeks; 87.5% of Week 44 responders maintained remission to Week 140.
|
|
| |
Next Steps
Reinforces Tremfya’s IBD expansion and J&J immunology leadership.
|
| |
Asset Snapshot
Durable remission, steroid independence, and mucosal healing via IL-23 targeting.
|
| |
These findings highlight Tremfya’s potential for long-term UC control over nearly three years.
|
| |
Solid Tumors
|
| |
|
| |
IDEAYA Biosciences doses first patient in Phase I trial of IDE034 (B7H3/PTK7 bispecific TOP1 ADC), evaluating safety, PK, and future combos in solid tumors.
|
| |
Key Details
|
| |
| • | Dual antigen targeting (B7H3/PTK7) + topoisomerase I payload for enhanced selectivity/cytotoxicity.
|
|
| • | Planned combos with DDR agents (e.g., proprietary PARG inhibitor IDE161) via synthetic lethality.
|
|
| • | Triggers $5M milestone to Biocytogen under license agreement.
|
|
| |
Next Steps
Dose escalation/expansion to support monotherapy and combo strategies.
|
| |
Asset Snapshot
Next-gen bispecific ADC with DDR synergy potential.
|
| |
IDE034 advances IDEAYA’s precision oncology push in the competitive ADC space.
|
| |
Ocular Myasthenia Gravis (MG)
|
| |
argenx reports positive Phase III ADAPT OCULUS data for Vyvgart (efgartigimod alfa and hyaluronidase-qvfc; SC weekly x4 cycles) vs. placebo in adults with ocular MG.
|
| |
Key Details
|
| |
| • | Primary endpoint met: MII PRO ocular score improvement of 4.04 points at Week 4 (vs. 1.99 placebo).
|
|
| • | Meaningful reductions in diplopia and ptosis.
|
|
| |
Next Steps
Full data at upcoming conference; sBLA submission to FDA planned.
|
| |
Asset Snapshot
FcRn-targeted SC therapy extending to high-unmet-need ocular subset.
|
| |
These results position Vyvgart for expansion across MG spectrum.
|
| |
HIV
|
| |
|
| |
ViiV Healthcare reports 12-month Phase IIb EMBRACE data for lotivibart (IV/SC Q4M) + cabotegravir LA (IM monthly) vs. oral SoC.
|
| |
Key Details
|
| |
| • | Viral suppression at Month 12: 94% (IV), 82% (SC) vs. 88% SoC.
|
|
| • | Confirmed virologic failure: 4% (IV), 6% (SC) vs. 4% SoC.
|
|
| |
Next Steps
Supports twice-yearly IV evaluation; presented at CROI 2026.
|
| |
Asset Snapshot
Ultra-long-acting backbone enabling simplified HIV regimens.
|
| |
These results advance ViiV’s leadership in long-acting HIV therapies.
|
| |
mCRPC (Bone Metastases)
|
| |
Bayer reports Phase III PEACE-3 data for Xofigo (radium-223 dichloride; IV 55 kBq/kg monthly ×6) + enzalutamide (160 mg QD) vs. enzalutamide alone.
|
| |
Key Details
|
| |
| • | OS: 38.2 vs. 32.6 months (24% risk reduction).
|
|
| • | rPFS: 19.4 vs. 16.4 months (HR 0.69).
|
|
| |
Next Steps
Presentation at ASCO GU 2026; published in Annals of Oncology.
|
| |
Asset Snapshot
Dual targeting delays progression and extends survival in bone-dominant disease.
|
| |
These findings reinforce Xofigo’s combo potential in mCRPC.
|
| |
Prurigo Nodularis
|
| |
Galderma reports 4-year OLYMPIA LTE data for Nemluvio in 508 patients from Phase II/III trials.
|
| |
Key Details
|
| |
| • | Week 148: >70% IGA clear/almost clear; >85% ≥75% healed lesions (prurigo activity score).
|
|
| • | 85% itch reduction; ~75% itch-free/nearly itch-free; ~90% meaningful QOL gains (DLQI 0-1 in >50%).
|
|
| |
Next Steps
Presentation at 2026 Winter Clinical Miami.
|
| |
Asset Snapshot
Durable skin clearance, itch control, and QOL gains over 4 years.
|
| |
These findings position Nemluvio as transformative long-term therapy for prurigo nodularis.
|
| |
|
| |
| | Regulatory Watch: Breakthrough Approvals
|
|
|
|
|
| |
Regulatory Spotlight: Approvals Surge in Rare Diseases, Oncology & Immunology
|
| |
|
| |
The global regulatory landscape is heating up, with multiple approvals and filings expanding treatment options and signaling strong momentum for innovative therapies:
|
| |
| • | Vanda Pharmaceuticals reports that the US FDA has approved Bysanti (milsaperidone) for acute bipolar I disorder and schizophrenia, offering a fresh tool for rapid symptom management.
|
|
| • | AstraZeneca announces FDA approval of the Calquence regimen for chronic lymphocytic leukemia (CLL), reinforcing its position in hematology.
|
|
| • | Immedica Pharma receives FDA accelerated approval for Loargys to treat hyperargininemia in ARG1-D patients, marking a major win in rare metabolic disease.
|
|
| • | Johnson & Johnson submits an sBLA for Imaavy, targeting warm autoimmune hemolytic anemia and expanding its hematology portfolio.
|
|
| • | Regeneron and Sanofi secure FDA approval for Dupixent in allergic fungal rhinosinusitis (AFRS), opening new doors in immunology care.
|
|
| • | Pfizer reports full FDA approval of the Braftovi regimen for metastatic colorectal cancer, strengthening its precision oncology offerings.
|
|
| • | GSK announces NMPA acceptance with priority review of Linerixibat for cholestatic pruritus and MHLW acceptance of Bepirovirsen for chronic hepatitis B, marking key international regulatory progress.
|
|
| • | Boehringer Ingelheim receives FDA accelerated approval for Hernexeos as first-line therapy for HER2-mutant NSCLC, expanding precision oncology options.
|
|
| • | Ionis Pharmaceuticals reports that the FDA has granted priority review for Olezarsen sNDA in severe hypertriglyceridemia, potentially transforming cardiovascular risk management.
|
|
| |
From rare diseases to oncology to immunology, this wave of approvals and regulatory milestones highlights the accelerating pace of innovation—and offers a glimpse at the next generation of therapies poised to transform patient care.
|
| |
|
| |
| | CARA System FDA Cleared for 3D Mapping
|
|
|
|
|
| |
Cara Medical’s CARA System Gains FDA Clearance for 3D Cardiac Mapping
|
| |
|
| |
Cara Medical has received 510(k) clearance from the US FDA for its CARA System, enabling noninvasive, patient-specific 3D visualization of the cardiac conduction system. Commercialization is expected in the coming months.
|
| |
The CARA System integrates the CARA Metis Simulator, a preprocedural CTA-based tool that generates personalized 3D conduction maps, with the CARA Atlas Navigator, which overlays these models onto live fluoroscopy during procedures. The system is designed to support preplanning and guidance for interventions near the cardiac conduction system, including TAVR, other percutaneous or surgical procedures, and therapies such as conduction system pacing, aiming to enhance precision, safety, and procedural outcomes.
|
| |
|
| |
| | FDA Accepts BLA for DRL_AB, Orencia Biosimilar
|
|
|
|
|
| |
FDA Accepts BLA for DRL_AB, a Proposed Interchangeable Orencia Biosimilar
|
| |
|
| |
Dr. Reddy’s has announced that the US FDA has accepted its 351(k) BLA for DRL_AB (IV), a proposed interchangeable biosimilar to Orencia (abatacept).
|
| |
If approved, DRL_AB could provide a cost-effective treatment option for adults with moderate to severe rheumatoid arthritis, adults with active psoriatic arthritis, and children aged six and older with polyarticular juvenile idiopathic arthritis.
|
| |
The BLA is backed by strong clinical evidence: the Phase I AB-01-003 trial showed pharmacokinetic similarity to Orencia with comparable safety and immunogenicity, while the ongoing Phase III AB-01-004 study continues to evaluate efficacy and safety, moving DRL_AB closer to offering a fully interchangeable alternative for immune-mediated arthritis patients.
|
| |
|
| |
| | FDA Approves Numelvi for Canine Itch
|
|
|
|
|
| |
Merck Animal Health’s Numelvi Gains FDA Approval for Canine Allergic Dermatitis
|
| |
|
| |
Merck Animal Health has announced that the US FDA has approved Numelvi (Atinvicitinib) for the control of pruritus associated with allergic dermatitis in dogs aged six months and older. Availability is expected in spring 2026.
|
| |
Numelvi is a second-generation JAK inhibitor, supplied in easy-to-dispense bottles and designed for convenient storage under standard conditions. It is over 10-fold more selective for JAK1 compared with JAK2, JAK3, and TYK2, targeting the cytokines that drive itch and inflammation in allergic and atopic dermatitis. This high selectivity supports both efficacy and a favorable safety profile, offering veterinarians a potent, targeted option to improve comfort and quality of life for dogs suffering from chronic pruritus.
|
| |
|
| |
|
| |
Pharma Power Moves: Deals, Approvals & Pipeline Breakthroughs
|
| |
GSK, Gilead, and Astellas lead the latest pharma power moves with multi-billion-dollar acquisitions and partnerships advancing respiratory, oncology, and prostate cancer pipelines. Regulatory momentum accelerates as FDA approves Merck Animal Health’s Numelvi for canine dermatitis, DRL_AB biosimilar for arthritis, and multiple rare-disease, oncology, and immunology therapies. Sciwind, Pfizer, Novo Nordisk, and Boehringer expand metabolic, immunology, and oral biologics portfolios, while Cara Medical gains 510(k) clearance for 3D cardiac mapping. PharmaShots delivers these insights for decision-makers in minutes.
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
Biopharma never sleeps — breakthrough data lands overnight, billion-dollar deals reshape markets, and regulatory moves redraw the competitive map in real time. Your intelligence can’t afford to lag.
|
| |
PharmaShots Weekly cuts through the noise, delivering what truly matters — pivotal pipeline updates, regulatory inflection points, clinical breakthroughs, strategic transactions, and competitive dynamics — distilled into a crisp, executive-ready brief you can absorb in minutes, not hours.
|
| |
Every Monday at 8:00 AM EST, get a clear, decision-focused snapshot of the forces shaping global pharma and biotech — curated for leaders who act on insight, not overwhelm.
|
| |
| | Tell your success story to world!
Reach out to us [email protected] for CXO Talks or Viewpoint interview, because your story matters!
|
|
|
|
|
| |
|
0 comments